London pre-open: Stocks expected to fall ahead of FOMC minutes
21st Aug 2013 07:26
Markets are expected to open lower on Wednesday morning as traders nervously await the minutes of the latest Federal Reserve meeting. City sources predict the FTSE 100 will open down 12 points after hitting a six-week low of 6,453.46 yesterday. Market sentiment has been a little fragile ahead of
Read moreHikma Pharmaceuticals raises full year guidance
21st Aug 2013 07:08
Hikma Pharmaceuticals said it had made a strong start to the first half of its financial year, with all of its businesses performing well, as it raised its guidance to around 20 per cent revenue growth for the year. The multinational pharmaceutical firm said revenue increased by 19.9% to $638.3m in
Read moreFriday broker round-up UPDATE
9th Aug 2013 07:29
Aquarius Platinum: Deutsche Bank lowers target price from 63p to 60p keeping a buy recommendation. Ashmore Group: HSBC ups target price from 400p to 435p, while keeping overweight rating. ASOS: UBS raises target price from 4600p to 6000p staying with its buy recommendation. Aviva: Bank of America
Read moreLondon close: Economists wax optimistic on UK
8th Jul 2013 17:08
Stocks registered a solid gain on Monday on the back of an advance in the banking sector. That came on the heels of what some economists termed a solid jobs report last Friday Stateside and upwards revisions to growth forecasts for the UK. Leading gains were shares of Royal Bank of Scotland, as Ch
Read moreFTSE 250 movers: Hikma, Bovis, Betfair, Balfour Beatty
8th Jul 2013 13:35
Pharmaceutical group Hikma Pharmaceuticals topped the leaderboard after saying it expects revenue to grow by 17 per cent in 2013 compared to its previous guidance of 13 per cent. Bovis Homes Group gained after announcing its reservations in the first half were ahead of its expectations amid signs o
Read moreMonday broker round-up UPDATE
8th Jul 2013 08:48
Anglo American: Exane reduces target price from 1700p to 1400p and reiterates its underperform rating. Anite Group: Investec raises target price from 135p to 155p and upgrades from hold to buy. Ashmore Group: RBC Capital Markets takes target price from 440p to 375p and keeps its neutral rating. B
Read moreLondon open: Positive start after strong US jobs
8th Jul 2013 08:04
London's leading shares started the week on strong footing after Friday's better than expected US nonfarm payrolls number and as focus turns to European Central Bank (ECB) President Mario Draghi's speech to European Parliament. Friday's widely watched report from the Labor Department showed US empl
Read moreHikma lifts full year revenue guidance
8th Jul 2013 07:06
Hikma Pharmaceutical said all of its businesses have continued to perform well and overall it expects revenue to grow by around 17 per cent in 2013, up from previous guidance of around 13 per cent. Across its main businesses, generics continued to benefit from strong doxycycline sales. Given the st
Read moreHikma Pharmaceuticals signs deal with Theravance for Vibativ
1st Jul 2013 09:04
Hikma Pharmaceuticals has signed an exclusive commercialisation agreement with Theravance for Vibativ in the Middle East and North Africa (MENA). Vibativ is a bactericidal, once-daily antibiotic for bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a dang
Read moreMonday broker round-up UPDATE
17th Jun 2013 07:21
Antofagasta: UBS reduces target price from 1140p to 1050p, while upgrading from neutral to buy. ARM Holdings: Analysts at Numis have cut their view on the shares to reduce from hold. Associated British Foods: Nomura cuts target price from 1800p to 1650p downgrading to reduce. Atkins: Jefferies u
Read moreHikma Pharmaceuticals shrinks stake
24th May 2013 15:36
Said Darwazah, the Chief Executive Officer of Hikma Pharmaceuticals, has reduced his stake in the FTSE 250 company, it was announced after Thursday's close. The director, who was the Minister of Health for the Hashemite Kingdom of Jordan from 2003 to 2006, sold 188,445 shares over a period of six d
Read moreWednesday broker round-up UPDATE
22nd May 2013 09:37
Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation. Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation. Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.
Read moreHikma Pharmaceuticals non-exec sells 5,700 shares
21st May 2013 15:52
Ronald Goode, a non-Executive Director of Hikma Pharmaceuticals, has disposed of 5,700 shares at 983.00p each. The £56,031 sale comes less than a week after the company upgraded its 2013 revenue growth forecast following a strong start to the year. In an announcment released May 16th, the group t
Read moreHikma Pharmaceuticals upgrades 2013 revenue outlook
16th May 2013 12:23
Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year". The group expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics
Read moreLondon close: Stocks hit by fears over growth, US earnings
17th Apr 2013 16:50
Fears over economic growth and a raft of disappointing earnings in the States weighed heavily on global markets on Wednesday, while a number of heavyweight stocks going ex-dividend dampened the FTSE 100 in London. Bank of America (BofA) was the first major US bank to miss forecasts this earnings se
Read more